| 佟士骅,张洁函,庄少伟,王玉华,居海宁.心可舒片治疗冠心病患者PCI术后焦虑的疗效及对生活质量的影响[J].,2018,(2):305-308 |
| 心可舒片治疗冠心病患者PCI术后焦虑的疗效及对生活质量的影响 |
| Clinical Efficacy of Xinkeshu Tablets in the treatment of Coronary Heart Disease Patients with Depression after PCI and Effect on the Quality of Life |
| 投稿时间：2017-09-18 修订日期：2017-09-30 |
| DOI：10.13241/j.cnki.pmb.2018.02.025 |
| 中文关键词: 冠心病 经皮冠状动脉介入 心可舒片 焦虑 生活质量 |
| 英文关键词: Coronary heart disease Percutaneous coronary intervention Xinkeshu tablets Depression Quality of life |
| 基金项目:上海市科委科技支撑项目（16ZR1428300) |
|
| 摘要点击次数: 532 |
| 全文下载次数: 366 |
| 中文摘要: |
| 摘要 目的：探讨心可舒片治疗冠心病(CAD)患者经皮冠状动脉介入(PCI)术后焦虑的疗效及对生活质量的影响。方法：选择2015年1月~2017年1月我院心内科收治的68例行PCI术后合并焦虑的CAD患者并将其随机分为治疗组(n=34)、对照组(n=34)。对照组给予常规药物治疗，治疗组在此基础上给予心可舒片，4片/次，3次/d，治疗周期为3个月。比较两组患者治疗前后血液流变学指标、焦虑症状、生活质量的变化。结果：治疗3个月后，治疗组患者全血黏度、血浆黏度、红细胞压积及血小板聚集率均较治疗前显著下降，且均明显低于对照组(P<0.05)；治疗1个月后，两组HAMA评分均较治疗前明显减低(P<0.05)，而两组间比较差异无统计学意义(P>0.05)；治疗3个月后，治疗组HAMA评分明显低于对照组(P<0.05)；治疗1、3个月后，两组WHOQOL-BREF各维度评分均较治疗前明显升高 (P<0.05)，且治疗组心理、社会关系维度评分显著高于对照组(P<0.05)。结论：心可舒片可改善CAD患者PCI术后合并焦虑患者的血液流变学，缓解焦虑症状，提高患者的生活质量。 |
| 英文摘要: |
| ABSTRACT Objective: To explore the clinical efficacy of Xinkeshu Tablets in the treatment of coronary heart disease(CAD) patients with depression after percutaneous coronary intervention (PCI) and effect on the quality of life(QOL). Methods: 68 cases of patients with CAD and depression after PCI were randomly divided into the treatment group (n=34) and the control group (n=34). The control group was given routine drug treatment, while the treatment group was given Xinkeshu tablets for 4 tablets each time,3 times a day on the basis of control group. The treatment course was 3 months. The changes of hemorheology indexes, anxiety symptoms, QOL after PCI were compared between two groups. Results: After treatment, the blood viscosity, plasma viscosity, hematokrit and platelet aggregation rate were significantly lower than those before treatment. At 1 month after treatment, the HAMA score in both groups were all remarkably reduced(P<0.05), and there was no significant difference on the the HAMD score between two groups(P>0.05). At 3 months after treatment, the HAMA score in treatment group was significantly reduced than that in the control group(P<0.05). At 1, 3 months after treatment, the WHOQOL-BREF score of each dimension were significantly increased than those before treatment(P<0.05), and the psychological, social relations dimension scores in treatment group were significantly higher than those in the control group(P<0.05). Conclusion: Xinkeshu tablets can improve the hemorheology, reduce the anxiety symptoms, improve the QOL in the treatment of CAD patients with depression after PCI. |
|
查看全文
查看/发表评论 下载PDF阅读器 |
| 关闭 |
